We keep a running list of the quiet, unglamorous projects that never make a company blog: the ones a single operations lead starts on a Tuesday because someone in finance asked an uncomfortable question. This is one of those. A reader at a 640-person fintech in the Midwest — we'll call her Dana, and we'll call the company Meridian — shared the full timeline of a benefits overhaul that started with a spreadsheet and ended with a different way of thinking about hearing care.
The uncomfortable question was simple: why had the company's hearing-aid reimbursement line tripled in two years while employee satisfaction with the benefit stayed flat? Dana pulled the claims data and found the pattern. Employees were getting devices through a patchwork of local clinics, paying wildly different prices, and often abandoning the aids within months. Nobody owned the outcome. That's when she started looking at direct-to-consumer hearing options, and RightEar surfaced early in her research.
The decision points
Dana's first instinct was to treat this as a procurement problem: get three quotes, pick the cheapest, move on. Her second instinct — the one that stuck — was to treat it as an adoption problem. The real cost wasn't the device; it was the 60% of employees who never wore the thing after week three.
She set three criteria before taking any meetings:
- Transparent, published pricing so employees could see what the company covered and what they'd owe.
- A trial long enough to survive the adjustment period, which everyone told her was the hardest part.
- Devices discreet enough that people would actually wear them in open-plan offices and on client calls.
The third criterion was the one that eliminated most vendors. Dana told us she sat through four demos where the pitch was entirely about audiology specs and none of it addressed why a 38-year-old account manager would feel self-conscious wearing the product in a meeting. RightEar's positioning — clinical-grade devices with discreet styling — was the first thing that matched what her employees had actually told her in a 22-person listening session.
The obstacles
Nothing about this went smoothly. The first obstacle was internal: Meridian's benefits broker had an existing relationship with a legacy hearing network and pushed back hard. Dana had to build a one-page comparison showing total cost of ownership over 24 months, factoring in replacement rates. The math favored the direct model, but only because the legacy network's abandonment rate was so high.
The second obstacle was cultural. A handful of employees assumed anything sold online was lower quality. Dana addressed this by running a small pilot with 9 volunteers, all of whom had previously used clinic-purchased devices. She asked them to log daily wear time and a simple comfort score. The pilot ran for 60 days — matching the in-home trial window — and the wear-time data was the turning point. Median daily wear went from just under 3 hours with the old devices to over 7 with the new ones. That's not a clinical claim; it's what nine people wrote in a shared spreadsheet.
The third obstacle was the least expected: tinnitus. Four of the nine pilot participants mentioned ringing in their ears as a reason they'd stopped wearing their old aids. Dana hadn't planned for this at all, and it forced a second round of research into tinnitus support technology. The pilot group ended up using those features heavily, and two participants said it was the single reason they kept wearing the devices past week two.
The measurable results
Meridian rolled the benefit out company-wide in month four. By month nine, Dana had numbers worth sharing:
- Participation rose from 14 employees per year to 61 in the first nine months.
- Average out-of-pocket cost per employee dropped by roughly 40%, mostly because published pricing eliminated surprise clinic fees.
- Device return rate within the trial window fell to 11%, versus 34% under the old network.
- Self-reported daily wear time held above 6 hours at the six-month mark.
The part Dana didn't expect was the recruiting angle. Two candidates in final-round interviews asked about the hearing benefit specifically, and one mentioned it in her acceptance note. For a company competing for experienced finance talent, that's a small but real signal.
What we took from it
We've watched a lot of benefits and operations projects get sold on features and die on adoption. This one worked because Dana front-loaded the human question — will people actually wear these — and let the pricing and trial structure do the rest. RightEar's 60-day in-home trial wasn't a gimmick in this context; it was the mechanism that let a skeptical pilot group prove the case to the rest of the company.
If you're running a similar evaluation, the useful takeaway isn't the vendor name. It's the sequence: listen first, pilot small, measure wear time rather than satisfaction, and only then negotiate. You can see how the trial and pricing structure work on RightEar's how-it-works page before you build your own comparison sheet. Dana's spreadsheet is still the template we send to readers who ask.